Mantle Cell Lymphoma: Biologic Insights to Bedside Impact

Since the recognition of mantle cell lymphoma (MCL) as a distinct entity within B-cell non-Hodgkin lymphoma, progress in the evolution of treatment has occurred at a pace perhaps more rapid than any other lymphoma subtype. Better diagnostic and prognostic tools extending from cytogenetics, immunohistochemistry (SOX11, Ki-67), and assessment of p53 status have augmented clinical assessments (such as the Mantle Cell International Prognostic Index) to define heterogeneity among MCL patients. While chemotherapy-based treatment has long been a mainstay of management, novel agents targeting the cell cycle, Bruton's Tyrosine Kinase (BTK), and new immune-based approaches have undoubtedly improved patient outcomes.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Tags: Preface Source Type: research